BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels. RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.
BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumorpatients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral gliomapatients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels. RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral gliomapatients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.
Authors: Wolfgang Gartner; Aysegül Ilhan; Dashurie Neziri; Wolfgang Base; Michael Weissel; Adelheid Wöhrer; Harald Heinzl; Thomas Waldhör; Ludwig Wagner; Matthias Preusser Journal: Neuro Oncol Date: 2010-04-08 Impact factor: 12.300
Authors: M Landriscina; G Schinzari; G Di Leonardo; M Quirino; A Cassano; E D'Argento; L Lauriola; M Scerrati; I Prudovsky; C Barone Journal: J Neurooncol Date: 2006-06-14 Impact factor: 4.130
Authors: Tao Yan; Kai Ove Skaftnesmo; Lina Leiss; Linda Sleire; Jian Wang; Xingang Li; Per Øyvind Enger Journal: BMC Cancer Date: 2011-12-20 Impact factor: 4.430
Authors: Troels Bechmann; Jonna Skov Madsen; Ivan Brandslund; Erik Dalsgaard Lund; Tina Ormstrup; Erik Hugger Jakobsen; Anne Marie Bak Jylling; Karina Dahl Steffensen; Anders Jakobsen Journal: Oncol Lett Date: 2013-08-19 Impact factor: 2.967
Authors: Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244